<div id="readability-page-1"><p>GLOBALT Investments LLC GA lifted its position in  Amgen Inc. (NASDAQ:AMGN - Free Report) by 25.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 25,923 shares of the medical research company's stock after acquiring an additional 5,247 shares during the quarter. GLOBALT Investments LLC GA's holdings in Amgen were worth $8,485,000 at the end of the most recent reporting period.</p><ul><li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li></ul><p>Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Anfield Capital Management LLC boosted its holdings in  Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after purchasing an additional 70 shares during the last quarter.  Dogwood Wealth Management LLC grew its position in  Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after purchasing an additional 55 shares in the last quarter.  Board of the Pension Protection Fund purchased a new stake in  Amgen in the 4th quarter valued at about $26,000.  Manning &amp; Napier Advisors LLC lifted its position in shares of  Amgen by 49.2% during the 4th quarter. Manning &amp; Napier Advisors LLC now owns 97 shares of the medical research company's stock worth $32,000 after buying an additional 32 shares in the last quarter.  Finally, Olistico Wealth LLC bought a new position in shares of  Amgen during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own  76.50% of the company's stock. </p><h2>Amgen Price Performance</h2><p>AMGN opened at $326.31 on Monday. The firm has a market cap of $176.10 billion, a P/E ratio of 22.71, a PEG ratio of 3.28 and a beta of 0.44. The firm has a 50-day moving average of $349.17 and a 200 day moving average of $343.36. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a fifty-two week low of $267.73 and a fifty-two week high of $391.29. </p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS.  On average, research analysts expect that  Amgen Inc. will post 22.37 EPS for the current year. </p><h2>Amgen Dividend Announcement</h2><p>The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen's dividend payout ratio  is presently 70.15%. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Several equities analysts have recently issued reports on the company. Argus upped their target price on Amgen from $360.00 to $400.00 and gave the company a &#34;buy&#34; rating in a report on Friday, February 6th. Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $285.00 to $295.00 and gave the company a &#34;hold&#34; rating in a research report on Thursday, February 5th. Truist Financial increased their price target on Amgen from $325.00 to $327.00 and gave the company a &#34;hold&#34; rating in a research report on Friday, May 1st. UBS Group increased their price target on Amgen from $390.00 to $400.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, April 13th. Finally, Piper Sandler decreased their price target on Amgen from $432.00 to $427.00 and set an &#34;overweight&#34; rating for the company in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Amgen  has a consensus rating of &#34;Hold&#34; and a consensus price target of $356.15.</p><p><b>Check Out Our Latest Stock Report on Amgen</b></p><h2>Insiders Place Their Bets</h2><p>In related news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders own  0.85% of the company's stock. </p><h2>About Amgen</h2> (Free Report)<p>Amgen Inc <span>NASDAQ: AMGN<span></span></span> is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.  </p><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p><h2>Read More</h2><ul><li>Five stocks we like better than Amgen</li><li>Robinhood, SoFi, and Webull Are Telling Very Different Stories</li><li>As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In</li><li>Target the Red-Hot Spin-Off and Merger Space With These ETFs</li><li>Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amgen Right Now?</h2><p>Before you consider Amgen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p><p>While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMGN

<p>GLOBALT Investments LLC GA increased its stake in Amgen Inc. by 25.4% in Q4, owning 25,923 shares valued at $8.49 million. Other institutional investors also adjusted their positions in Amgen. The company reported $5.15 EPS for the last quarter, exceeding estimates, and declared a quarterly dividend of $2.52 per share. Analysts have varied price targets for Amgen, with ratings ranging from Strong Buy to Sell.</p>

Market Beat

Amgen

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

iShares Biotechnology ETF

Ark Genomic Revolution ETF

VG Health

iShares US Pharma

ALPS Medical Breakthrough

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Deutsche Bank AG

Truist Financial

UBS Group AG

Piper Sandler Cos

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

GLOBALT Investments LLC GA Has $8.49 Million Stock Holdings in Amgen Inc. $AMGN